Drug International Limited launched Bicalon

Drug International Limited launched Bicalon as Anticancer drug. Bicalon is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate.